Proactive Investors
05 Aug 2026, 13:46 UTC · 1h ago
Eli Lilly shares rise on revenue beat, raised outlook
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
05 Aug 2026, 13:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Eli Lilly raised its full-year 2026 revenue outlook to a range of $85 billion to $87 billion, up from the previous $82 billion to $85 billion range. — An upward revision of full-year guidance by a mega-cap pharma leader signals strong sustainable growth and usually triggers significant price appreciation.
+0.80Second quarter revenue reached $22.97 billion, beating Wall Street estimates of $20.6 billion, driven by strong sales of Mounjaro and Zepbound. — A substantial beat on top-line revenue confirms the high market demand for GLP-1 weight-loss and diabetes drugs.
+0.70Lilly increased its full-year performance margin guidance to 49%–50.5% from the previous 47%–48.5%. — Improved margin guidance suggests better operational efficiency and pricing power despite some realized price declines.
+0.50Continue reading
6 related stories
Top 2 movers · tap to explore
Full-year non-GAAP EPS guidance was slightly adjusted downward to a range of $35.50 to $36.50 from $35.50 to $37.00 due to $3.03 per share in acquired R&D charges. — While primarily an accounting charge for business development, a lower EPS ceiling can temper the enthusiasm from the revenue beat.
-0.20Realized prices for Lilly's products declined 13% overall, with a 36% drop in international markets partly due to Mounjaro entering China's National Reimbursement Drug List. — Price erosion is a long-term headwind that partially offsets the positive impact of increased sales volume.
-0.20Which stocks this story touches
The company reported second quarter results that beat revenue and earnings expectations and raised its full-year revenue outlook.
The CEO discussed encouraging progress at the El Potrero project in Mexico.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
9m ago
